Barclays’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.6M | Sell |
471,300
-656,900
| -58% | -$52.6M | 0.01% | 944 |
|
|
2025
Q4 | $108M | Buy |
1,128,200
+998,200
| +768% | +$97.9M | 0.03% | 476 |
|
|
2025
Q3 | $12.7M | Sell |
130,000
-250,000
| -66% | -$25.9M | ﹤0.01% | 1506 |
|
|
2025
Q2 | $40.8M | Buy |
380,000
+206,500
| +119% | +$20.9M | 0.01% | 795 |
|
|
2025
Q1 | $17.5M | Buy |
173,500
+76,600
| +79% | +$7.71M | 0.01% | 1104 |
|
|
2024
Q4 | $8.66M | Sell |
96,900
-280,000
| -74% | -$24.6M | ﹤0.01% | 1682 |
|
|
2024
Q3 | $31.6M | Buy |
+376,900
| New | +$29.7M | 0.01% | 848 |
|
|
2024
Q2 | – | Sell |
-9,800
| Closed | -$671K | – | 4901 |
|
|
2024
Q1 | $671K | Buy |
+9,800
| New | +$630K | ﹤0.01% | 3405 |
|
|
2023
Q1 | – | Sell |
-82,600
| Closed | -$3.82M | – | 5106 |
|
|
2022
Q4 | $3.82M | Buy |
+82,600
| New | +$3.58M | ﹤0.01% | 1810 |
|
|
2022
Q1 | – | Sell |
-300
| Closed | -$13K | – | 4982 |
|
|
2021
Q4 | $13K | Hold |
300
| – | – | ﹤0.01% | 3976 |
|
|
2021
Q3 | $13K | Hold |
300
| – | – | ﹤0.01% | 4478 |
|
|
2021
Q2 | $13K | Hold |
300
| – | – | ﹤0.01% | 4575 |
|
|
2021
Q1 | $12K | Sell |
300
-213,400
| -100% | -$8.08M | ﹤0.01% | 4418 |
|
|
2020
Q4 | $7.68M | Sell |
213,700
-50,000
| -19% | -$1.8M | ﹤0.01% | 1285 |
|
|
2020
Q3 | $10.1M | Buy |
263,700
+247,200
| +1,498% | +$9.53M | 0.01% | 1034 |
|
|
2020
Q2 | $579K | Sell |
16,500
-194,500
| -92% | -$7M | ﹤0.01% | 3227 |
|
|
2020
Q1 | $6.88M | Buy |
211,000
+121,900
| +137% | +$4.76M | 0.01% | 1233 |
|
|
2019
Q4 | $4.03M | Buy |
89,100
+29,100
| +49% | +$1.22M | ﹤0.01% | 2250 |
|
|
2019
Q3 | $2.44M | Buy |
60,000
+35,400
| +144% | +$1.5M | ﹤0.01% | 2624 |
|
|
2019
Q2 | $1.06M | Buy |
24,600
+3,000
| +14% | +$115K | ﹤0.01% | 3631 |
|
|
2019
Q1 | $829K | Sell |
21,600
-113,600
| -84% | -$4.34M | ﹤0.01% | 3617 |
|
|
2018
Q4 | $4.78M | Buy |
135,200
+5,300
| +4% | +$192K | ﹤0.01% | 1636 |
|
|
2018
Q3 | $5M | Sell |
129,900
-490,400
| -79% | -$17.1M | ﹤0.01% | 1819 |
|
|
2018
Q2 | $20.3M | Buy |
620,300
+567,500
| +1,075% | +$17.1M | 0.02% | 777 |
|
|
2018
Q1 | $1.44M | Sell |
52,800
-117,700
| -69% | -$3.2M | ﹤0.01% | 2806 |
|
|
2017
Q4 | $4.23M | Buy |
170,500
+107,900
| +172% | +$2.98M | ﹤0.01% | 1797 |
|
|
2017
Q3 | $1.83M | Buy |
62,600
+48,800
| +354% | +$1.35M | ﹤0.01% | 2445 |
|
|
2017
Q2 | $383K | Buy |
13,800
+2,200
| +19% | +$58.4K | ﹤0.01% | 3772 |
|
|
2017
Q1 | $288K | Sell |
11,600
-70,500
| -86% | -$1.71M | ﹤0.01% | 3961 |
|
|
2016
Q4 | $1.78M | Sell |
82,100
-120,500
| -59% | -$2.63M | ﹤0.01% | 2229 |
|
|
2016
Q3 | $4.82M | Buy |
202,600
+76,100
| +60% | +$1.82M | 0.01% | 1328 |
|
|
2016
Q2 | $2.96M | Buy |
126,500
+120,200
| +1,908% | +$2.6M | ﹤0.01% | 1708 |
|
|
2016
Q1 | $113K | Sell |
6,300
-26,000
| -80% | -$457K | ﹤0.01% | 4265 |
|
|
2015
Q4 | $581K | Sell |
32,300
-8,500
| -21% | -$152K | ﹤0.01% | 3096 |
|
|
2015
Q3 | $653K | Buy |
40,800
+2,600
| +7% | +$44.4K | ﹤0.01% | 3114 |
|
|
2015
Q2 | $649K | Buy |
38,200
+3,600
| +10% | +$64.3K | ﹤0.01% | 3256 |
|
|
2015
Q1 | $588K | Sell |
34,600
-52,100
| -60% | -$823K | ﹤0.01% | 3447 |
|
|
2014
Q4 | $1.13M | Sell |
86,700
-140,200
| -62% | -$1.79M | ﹤0.01% | 3104 |
|
|
2014
Q3 | $2.5M | Buy |
226,900
+134,000
| +144% | +$1.69M | ﹤0.01% | 2455 |
|
|
2014
Q2 | $1.11M | Sell |
92,900
-102,300
| -52% | -$1.33M | ﹤0.01% | 3225 |
|
|
2014
Q1 | $2.54M | Sell |
195,200
-47,800
| -20% | -$627K | ﹤0.01% | 2311 |
|
|
2013
Q4 | $2.92M | Buy |
243,000
+183,600
| +309% | +$2.17M | ﹤0.01% | 2301 |
|
|
2013
Q3 | $654K | Buy |
59,400
+6,400
| +12% | +$69.2K | ﹤0.01% | 3811 |
|
|
2013
Q2 | $491K | Buy |
+53,000
| New | +$450K | ﹤0.01% | 4218 |
|
Other funds holding BSX
VCM
VPM
Barclays's BSX Position: Q1 2026 in Review
Barclays increased its Boston Scientific (BSX) stake by 15% in Q1 2026, buying an estimated $53.1M and bringing the position to 5,024,157 shares worth $315M. The position accounts for 0.08% of the portfolio, ranked #193.
Barclays first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $558M in Q1 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Barclays held 5,024,157 shares of Boston Scientific worth $315M as of Q1 2026.
- Barclays bought 663,465 Boston Scientific shares in Q1 2026, an estimated $53.1M.
- Boston Scientific made up 0.08% of Barclays's portfolio in Q1 2026, its #193 holding.
- Barclays first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
- Barclays's Boston Scientific position peaked at $558M in Q1 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.